PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28806393-8	2017	The pan-RAF dimer inhibitor, LY3009120, could suppress CRAF-fusion oncogenicity by inhibiting dimer-mediated signaling.	LY3009120	29-38	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	55-59	
27999210-7	2017	The anti-proliferative effects of LY3009120 in KRASmut CRC cell lines phenocopied molecular inhibition of RAF isoforms by simultaneous siRNA-mediated knockdown of ARAF, BRAF and CRAF.	LY3009120	34-43	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	178-182	
26343583-2	2015	Biochemical and cellular analyses revealed that LY3009120 inhibits ARAF, BRAF, and CRAF isoforms with similar affinity, while vemurafenib or dabrafenib have little or modest CRAF activity compared to their BRAF activities.	LY3009120	48-57	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	83-87	
26343583-3	2015	LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK, suggesting that it effectively inhibits the kinase activity of BRAF-CRAF heterodimers.	LY3009120	0-9	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	23-27	
26343583-3	2015	LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK, suggesting that it effectively inhibits the kinase activity of BRAF-CRAF heterodimers.	LY3009120	0-9	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	169-173	
26343583-4	2015	Further analyses demonstrated that LY3009120 also inhibits various forms of RAF dimers including BRAF or CRAF homodimers.	LY3009120	35-44	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	105-109